Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty

Journal of Arthroplasty

Volumn 30, Issue 7, 2015, Pages 1277-1280

  Charters, Michael A ^a   Frisch, Nicholas B ^a   Wessell, Nolan M ^a   Dobson, Christopher ^b   Les, Clifford M ^a   Silverton, Craig D ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DVT; Enoxaparin; Factor Xa inhibitor; PE; Rivaroxaban; VTE

Indexed keywords

ENOXAPARIN; RIVAROXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; REOPERATION; RETROSPECTIVE STUDY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; CHEMISTRY; COMPARATIVE STUDY; HEMORRHAGE; HIP REPLACEMENT; KNEE REPLACEMENT; MIDDLE AGED;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ENOXAPARIN; FACTOR XA INHIBITORS; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIVAROXABAN; VENOUS THROMBOEMBOLISM;

EID: 84931563194     PISSN: 08835403     EISSN: 15328406     Source Type: Journal    
DOI: 10.1016/j.arth.2015.02.009     Document Type: Article

References (17)

1. Kubitza D., Becka M., Voith B., et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78(4):412.
2. Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358(26):2765.
3. Kakkar A.K., Brenner B., Dahl O.E., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372(9632):31.
4. Lassen M.R., Ageno W., Borris L.C., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358(26):2776.
5. Turpie A.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373(9676):1673.
6. Eriksson B.I., Kakkar A.K., Turpie A.G., et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009, 91(5):636.
7. Lassen M.R., Gent M., Kakkar A.K., et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. J Bone Joint Surg Br 2012, 94(11):1573.
8. Russell R.D., Huo M.H. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty. J Arthroplast 2013, 28(9):1477.
9. Huisman M.V., Quinlan D.J., Dahl O.E., et al. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010, 3(6):652.
10. Turpie A.G., Lassen M.R., Eriksson B.I., et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011, 105(3):444.
11. Nieto J.A., Espada N.G., Merino R.G., et al. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thromb Res 2012, 130(2):183.
12. Kwong L.M. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data. Vasc Health Risk Manag 2011, 7:461.
13. Jensen C.D., Steval A., Partington P.F., et al. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br 2011, 93(1):91.
14. Jameson S.S., Rymaszewska M., Hui A.C., et al. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Am 2012, 94(17):1554.
15. Beyer-Westendorf J., Lutzner J., Donath L., et al. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. Thromb Haemost 2013, 109(1):154.
16. Chahal G.S., Saithna A., Brewster M., et al. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis. Ortop Traumatol Rehabil 2013, 15(2):125.
17. Duran A., Sengupta N., Diamantopoulos A., et al. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective. PharmacoEconomics 2012, 30(2):87.